Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.

    Sunday, March 25, 2007


    Session:          1206:  Vascular Disease, Hypertension and Prevention --

                      V-cast Poster


    Track:            ACC.Vascular Disease, Hypertension, and Prevention


    Room:             Hall H


    Presentation:     1206-278


    Abstract:         Statin-Like, Dose-Dependent Reductions in LDL-C and

                      Apolipoprotein B With ISIS 301012, an Antisense

                      Inhibitor of Apolipoprotein B, in Subjects With

                      Polygenic Hypercholesterolemia


    Monday, March 26, 2007


    Session:          603:  Common Challenges in Preventive Cardiology

                      (7:00 - 8:30 a.m. CT)


    Track:            ACC.Symposium


    Room:             Auditorium B


    Presentation:     603-8


    Time:             8:15 - 8:30 a.m.


    Speaker:          Dr. Evan A. Stein


    Title:            High Low-Density Lipoprotein Cholesterol on Three Drugs*

                      *to include preliminary results of an ongoing study

                      evaluating ISIS 301012 in HoFH patients on concurrent

                      maximally tolerated lipid-lowering therapies


    Session:          820:  Clinical Trials of 
Lipid-Lowering Therapy

                      (4:00 - 5:30 p.m. CT)


    Track:            ACC.Vascular Disease, Hypertension, and Prevention


    Room:             Auditorium B


    Presentation:     820-6


    Time:             4:45 - 5:00 p.m.


    Speaker:          Dr. John J.P. Kastelein


    Title:            ISIS 301012, an Antisense Inhibitor of Apolipoprotein B,

                      Produces Significant Additional Reduction of Low-Density

                      Lipoprotein Cholesterol and Apolipoprotein B in

                      Hypercholesterolemic Subjects on Statins Not Meeting

                      Target


    Tuesday, March 27, 2007


    Presentation:     Isis Pharmaceuticals' Live Analyst/Investor Webcast


    Time:             7:00 a.m. CT


    Where:            www.isispharm.com


    How:              Live over the Internet -- select the link on Isis' home

                      page at the address above.

If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of ov er 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of ISIS 301012 in treating high cholesterol and cardiovascular disease. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, which is on file with the SEC. Copies of this and other documents are available from the Company.

CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development ofIsis Pharmaceuticals, +1- -760-603-2331

Web site: http://www.isispharm.com/

Ticker Symbol: (NASDAQ-NM S:ISIS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader in ... its Series D investment round on February 5, 2016. ... Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, ... Partners, SCP Vitalife Partners, Generali Financial Holdings and both ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch ... recently identified an industry-wide trend regarding the evolution ... allows organizations to efficiently deliver compelling sales presentations ... 2011 and another in 2015, Intouch uncovered that ... tablet devices and DSAs, many are not using ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
Breaking Medicine Technology:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... AxoGen, ... market, will report results for the fourth quarter and full year ended December 31, ... host a conference call and webcast for the investment community following the release at ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club ... awarded the prestigious Distinguished Emerald Club of the World award, as determined by ... one of the most respected trade publications serving private clubs. , “We’d like ...
Breaking Medicine News(10 mins):